Exploring genetic factors in acute aortic conditions
Genetic Architecture of Acute Aortic Syndromes and Aortic Aneurysm.
This study is testing whether looking at the genes of people with aortic dissection or aneurysm can help doctors better predict who is at risk and improve their chances of getting timely treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 730 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Trial ID | NCT06353607 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the genetic information linked to acute aortic dissection and thoracic aortic aneurysm in individuals without a history of syndromic features. Whole genome sequencing will be performed on patients who have documented cases of aortic aneurysm or dissection. The study seeks to improve risk prediction tools for identifying high-risk patients, which could lead to timely diagnosis and surgical intervention, ultimately reducing morbidity and mortality associated with these conditions.
Who should consider this trial
Good fit: Ideal candidates include adult patients over 18 years who have undergone or will undergo surgery for acute aortic dissection or thoracic aortic aneurysm at the University Hospital Basel.
Not a fit: Patients with diagnosed heritable vascular disorders such as Marfan syndrome or Ehlers-Danlos syndrome may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better risk assessment and management strategies for patients at risk of acute aortic syndromes.
How similar studies have performed: Previous studies have indicated a genetic component in thoracic aortic aneurysm and dissection, suggesting that this approach has potential based on existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult patients \> 18 years who underwent surgery for aAD or TAA intervention at the University Hospital Basel, starting in 2015. * All patients who will undergo surgery for aAD or TAA at the University Hospital Basel, beginning in 2024. Exclusion Criteria: * Patients will be excluded if they are not able or not willing to provide informed consent. * Patients with diagnosed heritable vascular disorders, such as Marfan syndrome, Turner Syndrome, Loeyes Dietz and Ehlers-Danlos syndrome.
Where this trial is running
Basel
- University Hospital Basel — Basel, Switzerland (Recruiting)
Study contacts
- Principal investigator: Denis Berdajs, Prof. Dr. — University Hospital, Basel, Switzerland
- Study coordinator: Denis Berdajs, Prof. Dr.
- Email: denis.berdajs@usb.ch
- Phone: 0041 61 328 71 80
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.